Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 July 2022 | Story Dr Nitha Ramnath | Photo Supplied
Leah Molatseli.


Leah Molatseli– alumna and Council member of the University of the Free State (UFS) – is the first African woman to be recognised by the American Bar Association in its list of Women of Legal Tech for her contribution and influence in the legal tech industry. A commitment to diversity is one of the core values of the American Bar Association, which the Law Practice Division aims to reinforce in the legal tech sector. Annually, talented women in the legal tech space are recognised for making an impact on legal tech.

A lawyer by profession, published legal tech author and speaker, as well as legal tech and innovation specialist, Molatseli uses technology and innovative means to empower and educate law professionals.  She is currently head of business development at Legal Interact, a South African law firm that provides technology solutions for the legal industry. 

Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, congratulated Molatseli on her achievement. “On behalf of the executive committee of the University of the Free State (UFS) and the university community, I would like to extend my warmest congratulations on being recognised by the American Bar Association for your contribution to the legal tech industry. Being the first African woman to be honoured in this way makes this accomplishment even more extraordinary. You are a trailblazer in your field in so many ways,” said Prof Petersen. 

Prof Petersen said, “The university, and the Faculty of Law in particular, is proud to be associated with you. We also appreciate your continued support to the institution. Your dedication and expertise inspire us all – I will continue to follow your professional journey, because I know there is much more in store”. Prof Petersen continued to thank Molatseli for contributing to the legal field in an innovative and contemporary manner. 

Molatseli is host of and guest speaker for various legal tech talks globally, as well as a guest lecturer at the University of Cape Town, where she develops and teaches legal tech innovation-related courses to the legal industry. A Mandela Washington fellow, as well as a Notre Dame alumna, she is a member of the Women in Tech South African Chapter, a country member for the Global Legal Tech Consortium, and is one of 2022’s ILTA’s Most Influential Women in Legal Tech honourees.  


News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept